Építés alatt – nem éles oldal
Belépés
FelfüggesztveNo phase

Cancer Risk Assessment in Patients With a Constitutional Alteration of the PTEN Gene

Megadott ok: Cyber attack of the enrollment system, new system on going to be implemented

Key facts

Where
Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Chambéry, Colmar, Dijon, Grenoble, Le Mans, Lille, Limoges, Lyon, Marseille, Montpellier, Nantes, Nice, Nîmes, Niort, Paris, Pointe à Pitre, Poitiers, Reims, Rennes, Rouen, Saint-Etienne, Strasbourg, Toulouse, Tours, Troyes, Valence és Villejuif, FranciaországSee the 45 sites

Where in Franciaország

  • 1-CHU AmiensAmiens, FranciaországNo longer taking part
  • 2-CHU AngersAngers, FranciaországNo longer taking part
  • 3-ICO Angers et NantesAngers, FranciaországNo longer taking part
  • 4-CHU BesançonBesançon, FranciaországNo longer taking part
  • 5-CHU BordeauxBordeaux, FranciaországNo longer taking part
  • 6-Institut BergoniéBordeaux, FranciaországNo longer taking part
  • 7-CHU BrestBrest, FranciaországNo longer taking part
  • 8-Centre François BaclesseCaen, FranciaországNo longer taking part
  • 9-CH Métropole Savoie ChambéryChambéry, FranciaországNo longer taking part
  • 10-CHU ColmarColmar, FranciaországNo longer taking part
  • 11-CHU DijonDijon, FranciaországNo longer taking part
  • 12-CHU GrenobleGrenoble, FranciaországNo longer taking part
  • 36-CH Le MansLe Mans, FranciaországNo longer taking part
  • 16-CHU LilleLille, FranciaországNo longer taking part
  • 17-CHU LimogesLimoges, FranciaországNo longer taking part
  • 18a-Hospices Civils Lyon - Lyon EstLyon, FranciaországNo longer taking part
  • 18b-Hospices Civils Lyon - Lyon SudLyon, FranciaországNo longer taking part
  • 19-AP-HM Hôpital de la TimoneMarseille, FranciaországNo longer taking part
  • 33-Institut Paoli CalmettesMarseille, FranciaországNo longer taking part
  • 20-CHU MontpellierMontpellier, FranciaországNo longer taking part
  • 21-CHU NantesNantes, FranciaországNo longer taking part
  • 22-CHU NiceNice, FranciaországNo longer taking part
  • 32-Centre Antoine LacassagneNice, FranciaországNo longer taking part
  • 23-CHU NîmesNîmes, FranciaországNo longer taking part
  • 37-CH NiortNiort, FranciaországNo longer taking part
  • 13a-AP-HP Hôpital AvicenneParis, FranciaországNo longer taking part
  • 13b-AP-HP Hôpital Saint-AntoineParis, FranciaországNo longer taking part
  • 13c-APH-HP Hôpital SalpétrièreParis, FranciaországNo longer taking part
  • 13d-AP-HP Hôpital TrousseauParis, FranciaországNo longer taking part
  • 13e-AP-HP Hôpital Saint-LouisParis, FranciaországNo longer taking part
  • 13f-AP-HP Hôpital Robert DebréParis, FranciaországNo longer taking part
  • 14-Institut CurieParis, FranciaországNo longer taking part
  • 38-CHU GuadeloupePointe à Pitre, FranciaországNo longer taking part
  • 24-CHU PoitiersPoitiers, FranciaországNo longer taking part
  • 25-Institut du Cancer CourlancyReims, FranciaországNo longer taking part
  • 26-Centre Eugène MarquisRennes, FranciaországNo longer taking part
  • 27-CHU RennesRennes, FranciaországNo longer taking part
  • 35-CHU RouenRouen, FranciaországNo longer taking part
  • 28-CHU Saint-EtienneSaint-Etienne, FranciaországNo longer taking part
  • 29-Institut StraussStrasbourg, FranciaországNo longer taking part
  • 30-CHU ToulouseToulouse, FranciaországNo longer taking part
  • 31-CHU ToursTours, FranciaországNo longer taking part
  • 40-CHU TroyesTroyes, FranciaországNo longer taking part
  • 34-CH ValenceValence, FranciaországNo longer taking part
  • 15-Institut Gustave RoussyVillejuif, FranciaországNo longer taking part

Trial details

Who runs it
Institut Bergonié
Trial code
NCT05630105
Record updated
2026. május 15.
Original description
This is a multicentric, observational, retrospective and prospective study, aiming to estimate the risk of cancer occurrence in subjects carrying a PTEN mutation, based on the constitution of a national cohort.Read full original descriptionShow less

National Cohort of Patients With Cowden's Disease and With a Constitutional Alteration of the PTEN Gene for the Prospective Assessment of the Risk of Cancer.

This is a multicentric, observational, retrospective and prospective study, aiming to estimate the risk of cancer occurrence in subjects carrying a PTEN mutation, based on the constitution of a national cohort.

Inclusion: Male or female; Adult or child without age limit; Carrier of a constitutional or mosaic alteration of the PTEN gene established and/or confirmed by the Institut Bergonié's genetics laboratory, following a request for molecular diagnosis made between 1997 and 2027; Participant informed of his genetic diagnosis; Participant informed and not having expressed non-opposition to participate in the research; Participant affiliated to a French social security system in accordance with French law on research involving the human person.

Exclusion: Persons under psychiatric care, persons admitted to a health or social establishment for purposes other than research; Exception: a participant with autism may be included in the study; Participant under guardianship or curatorship. Exception: a participant with autism may be included in the study; Persons deprived of their liberty by a judicial or administrative decision.

ClinicalTrials.gov NCT05630105